– Patient perspectives revealed frequent treatment delays, suboptimal clinical outcomes and substantial anxiety associated with injectable on-demand treatments, including those who received.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CFO Benjamin L. Palleiko Sells 22,802 Shares of Stock themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
KalVista Pharmaceuticals (NASDAQ:KALV) Given New $24.00 Price Target at HC Wainwright themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) – Leerink Partnrs lowered their Q3 2024 earnings per share (EPS) estimates for KalVista Pharmaceuticals in a research report issued on Tuesday, February 13th. Leerink Partnrs analyst J. Schwartz now expects that the specialty pharmaceutical company will post earnings per share of ($0.69) for the quarter, down from […]